MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2022-23)
- Udyam number
- UDYAM-TS-02-0006666
Aurore Pharmaceuticals Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹94.5 Cr
▲ 1% YoY
Net loss · FY 2025
₹20.93 Cr
Net margin -22.2%
EBITDA · FY 2025
-₹6.29 Cr
EBITDA margin -6.7%
Authorised capital
₹50 Cr
Registered with MCA
Paid-up capital
₹42.11 Cr
Issued & subscribed
Open charges
₹320 Cr
Satisfied ₹2.5 Cr
Company age
9 yrs
Est. 2017
Employees · EPFO
451
Provident fund records
About Aurore Pharmaceuticals Private Limited
Data last updated:
Aurore Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Aurore Life Sciences Private Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 15 May 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG2017PTC117032. Its GSTIN is 36AAYCS6500Q1ZF (Telangana).
The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹42.11 Cr. It was formerly known as Sphery Lifesciences Private Limited. It is led by directors Sailesh Jhawar Kumar and Sareddy Reddy Ravisankara.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot # 68 69 2nd Floor Jubilee Heights Beside Shilparamam Madhapur, Hyderabad, Telangana, India – 500081.
As per the financials filed for FY 2025, the company reported a revenue of ₹94.5 Cr, a growth of 1% compared to the previous year. For the same year it recorded a net loss of ₹20.93 Cr (net margin -22.2%) and EBITDA of -₹6.29 Cr (EBITDA margin -6.7%). Revenue has grown at a compounded annual rate (CAGR) of 30% over three years and 4% over five years.
The company has about 451 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Aurore Life Sciences. As per MCA filings, the company has open charges of ₹320 Cr and satisfied charges of ₹2.5 Cr on record. Court records list 8 cases involving the company, including 1 filed by the company and 7 filed against it; 5 cases are pending. The company has 3 deals on record (2 secondary share transfers, 1 rights issue); the latest was in March 2022. Its 8 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Enicar Pharmaceuticals Private Limited with revenue of ₹97.81 Cr. The company has 13 MSME Form 1 returns on record between 2019 and 2023, listing 828 overdue payments to 69 micro and small suppliers.
Aurore Pharmaceuticals Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0006666). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurorels.com.
Company details
CIN U24239TG2017PTC117032
Registration Number 117032
Incorporation Date 15 May 2017
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Aurore Life Sciences Private Limited
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-02-0006666
Recognitions & Rankings of Aurore Pharmaceuticals
Contact details
Aurore Pharmaceuticals Private Limited's registered office is in Hyderabad, Telangana. Its website is aurorels.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressPlot # 68 69 2nd Floor Jubilee Heights Beside Shilparamam Madhapur, Hyderabad, Telangana, India – 500081
- IndustryPharma, API Manufacturers
To see the full contact details of Aurore Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Aurore Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Aurore Pharmaceuticals operates one associated brand: Aurore Life Sciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Develops and produces Active Pharmaceutical Ingredients and intermediates for pharmaceutical markets. | aurorels.com |
Business activity
The main business activities of Aurore Pharmaceuticals are manufacturing and professional, scientific and technical. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and other professional, scientific and technical activities. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities |
To see the full business activity and turnover split of Aurore Pharmaceuticals Private Limited, buy the company report.
Financials of Aurore Pharmaceuticals Private Limited
FY 2025 filings availableAurore Pharmaceuticals Private Limited reported revenue of ₹94.5 Cr (up 1% YoY) for FY 2025.
Revenue · FY 2025
₹94.5 Cr ▲ 1%
Net loss · FY 2025
₹20.93 Cr margin -22.2%
EBITDA · FY 2025
-₹6.29 Cr margin -6.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 1%
3 years · compounded
▼ 30%
5 years · compounded
▲ 4%
EBITDA CAGR growth
1 year
▼ 44%
3 years · compounded
▼ 56%
5 years · compounded
▼ 10%
Revenue has grown at a compounded annual rate (CAGR) of 4% over five years, including 1% growth in the latest year. EBITDA fell 44% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹6.29 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹20.93 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -6.7% | ||||
| Net Profit Margin | -22.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Aurore Pharmaceuticals Private Limited, buy the company report.
Board of directors of Aurore Pharmaceuticals Private Limited
Aurore Pharmaceuticals has 2 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sareddy Reddy Ravisankara | Nominee Director | 06 Dec 2022 | 3 Years 10 Months | Current |
| Sailesh Jhawar Kumar | Director | 18 Sep 2024 | 2 Years 1 Months | Current |
Peer comparison
Aurore Pharmaceuticals Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Enicar Pharmaceuticals Private Limited | ₹97.81 Cr (FY 2025) | -1.0% | Boisar, Maharashtra, India | |||
| Teena Labs Limited | ₹96.94 Cr (FY 2024) | -46.0% | Hyderabad, Telangana, India | |||
| B G P Healthcare Private Limited | ₹95.66 Cr (FY 2025) | -1.0% | Ankleshwar, Gujarat, India | |||
| Virupaksha Laboratories Private Limited | ₹94.74 Cr (FY 2024) | 12.0% | Hyderabad, Telangana, India | |||
| Aurore Pharmaceuticals Private Limitedthis company | ₹94.5 Cr (FY 2025) | -₹20.93 Cr | -22.2% | 1.0% | 451 | Hyderabad, Telangana, India |
| Angels Pharma India Private Limited | ₹94.49 Cr (FY 2021) | 636.0% | Hyderabad, Telangana, India | |||
| Polypeptide Laboratories Private Limited | ₹94.1 Cr (FY 2025) | 34.0% | Ambernath, Maharashtra, India | |||
| Integrin Lifesciences Private Limited | ₹92.04 Cr (FY 2025) | 3.0% | Hyderabad, Telangana, India | |||
| Twentyfirst Century Pharmaceuticals Private Limited | ₹91.89 Cr (FY 2022) | 32.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Aurore Pharmaceuticals Private Limited, buy the company report.
Auditor
Aurore Pharmaceuticals Private Limited is audited by Deloitte Haskins & Sells for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Deloitte Haskins & Sells | FY 2022 | 008072S |
Shareholding
The shareholding of Aurore Pharmaceuticals Private Limited is on record for 4 financial years, the latest being FY 2022, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2022 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Aurore Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹320 Cr
Satisfied charges
₹2.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Sep 2024 | 101017337 | Others | ₹300 Cr | Open | |
| 29 May 2018 | 100197941 | Yes Bank Limited | ₹20 Cr | Open | |
| 15 Jun 2018 | 100198200 | Axis Bank Limited | ₹2.5 Cr | Satisfied |
To see the full charge records of Aurore Pharmaceuticals Private Limited, buy the company report.
Total charge records: 3 View all charges
Deals & funding
Aurore Pharmaceuticals Private Limited has 3 deals on record (2 secondary share transfers, 1 rights issue); the latest was in March 2022.
Total deals
3
Secondary share transfers
2
Rights issue
1
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: Aurore Life Sciences Private Limited , Aurore Life Sciences Private Limited & Pudhucode Radhakrishnan Kannan Seller: Spiracca Ventures LLP , Hydra Active Pharma Sciences Private Limited , an individual |
| Jan 2019 | Secondary share transfer | Undisclosed | Buyer: Hydra Active Pharma Sciences Private Limited , 2 individuals Seller: Hydra Active Pharma Sciences Private Limited , 2 individuals |
| May 2018 | Rights issue | ₹42.1 Cr | Investors: Hydra Active Pharma Sciences Private Limited , Spiracca Ventures LLP , 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Aurore Pharmaceuticals Private Limited has 8 court cases on record: 1 filed by Aurore Pharmaceuticals, 7 filed against it. 5 cases are pending and 3 are disposed.
Total cases
8
Filed by the company
1
Filed against the company
7
Pending
5
Disposed
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| NCLAT | 4 | 4 | 3 |
| NCLT | 2 | 2 | 0 |
| District courts | 1 | 1 | 1 |
| High courts | 1 | 0 | 1 |
Cases on record (5 of 8)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLAT, Court III | Tribunal matter | Filed against the company by Aurore Life Sciences Private Limited | Pending |
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed against the company by Aurore Life Sciences Private Limited | Pending |
| NCLAT, NCLAT Chennai | Court case (TA (AT)) | Filed against the company by Aurore Life Sciences Private Limited | Disposed |
| District court, Krishna, Andhra Pradesh | Civil suit | Filed against the company by individuals | Pending |
| High Court, TELANGANA | Writ petition | Filed by the company against Appellate Joint Commissioner (St) and 4 others | Pending |
To see the full case history of Aurore Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Aurore Pharmaceuticals Private Limited was last rated by Icra on 09 Jun 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 09 Jun 2022 |
To see the full credit ratings and regulatory alerts of Aurore Pharmaceuticals Private Limited, buy the company report.
MSME payment delays
Aurore Pharmaceuticals Private Limited has 13 MSME Form 1 returns on record between 2019 and 2023, listing 828 overdue payments to 69 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 69)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sree Venkata Sai Industries | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| Anusha Hospitality Services Private Limited |
To see the full MSME payment records of Aurore Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Aurore Pharmaceuticals Private Limited has a workforce of 451 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
Employee count
451
Active EPFO establishments
1
Employee growth
23.9%
GST
Aurore Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAYCS6500Q1ZF | Telangana | Active | 24 Apr 2018 |
To see the full GST registrations and return filing status of Aurore Pharmaceuticals Private Limited, buy the company report.
Recent activity
Aurore Pharmaceuticals Private Limited has 11 board changes on record since 2018: 2 appointments and 9 cessations. The latest: Vamsilatha Thulasi ceased to be Company Secretary on 04 Oct 2024.
AGM
Aurore Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge registered on 15 Jun 2018 via Charge ID 100198200 with Axis Bank Limited was fully satisfied on 03 Jun 2025.
Filing
Aurore Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge with Others of Rs. 300.00 Cr registered on 26 Sep 2024 with Charge ID 101017337 was modified on 19 Nov 2024.
Charges
A charge with Axis Bank Limited of Rs. 2.50 Cr registered on 15 Jun 2018 with Charge ID 100198200 was modified on 30 Oct 2024.
Charges
A charge with Yes Bank Limited of Rs. 20.00 Cr registered on 29 May 2018 with Charge ID 100197941 was modified on 30 Oct 2024.
Ceased
Vamsilatha Thulasi ceased to be Company Secretary.
Charges
A charge with Others amounted to Rs. 300.00 Cr with Charge ID 101017337 was registered on 26 Sep 2024.
Appointed
Sailesh Jhawar Kumar was appointed as Director.
Ceased
Krishna Yeachuri ceased to be Director.
Appointed
Sareddy Reddy Ravisankara was appointed as Nominee Director.
Ceased
Amit Purushottam Kaptain ceased to be Additional Director.
9 earlier events are in the company report.
Frequently asked questions
Aurore Pharmaceuticals is an active private limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 15 May 2017 (9+ years old) and is registered under CIN U24239TG2017PTC117032.
Aurore Pharmaceuticals has 2 current directors:
- Sareddy Reddy Ravisankara - Nominee Director
- Sailesh Jhawar Kumar - Director
The latest financial statements of Aurore Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Aurore Pharmaceuticals is 36AAYCS6500Q1ZF, registered in Telangana.
The CIN (Corporate Identification Number) of Aurore Pharmaceuticals is U24239TG2017PTC117032. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Aurore Pharmaceuticals has 8 court cases on record: 1 filed by the company and 7 filed against it. 5 are pending. Most are in the nclat.
Aurore Pharmaceuticals was incorporated on 15 May 2017, making it 9+ years old. It is registered with the Registrar of Companies, Hyderabad.
Aurore Pharmaceuticals has 3 deals on record (2 secondary share transfers, 1 rights issue); the latest was in March 2022.
The peers of Aurore Pharmaceuticals by revenue are Enicar Pharmaceuticals Private Limited, Teena Labs Limited, B G P Healthcare Private Limited, Virupaksha Laboratories Private Limited, Angels Pharma India Private Limited and 3 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Vamsilatha Thulasi ceased to be Company Secretary on 04 Oct 2024. Sailesh Jhawar Kumar was appointed as Director on 18 Sep 2024. Krishna Yeachuri ceased to be Director on 04 Jan 2023. Aurore Pharmaceuticals has 11 board changes on record in total.
Yes, Aurore Pharmaceuticals is registered as a medium enterprise under Udyam registration (number: UDYAM-TS-02-0006666).
Aurore Pharmaceuticals has 13 MSME Form 1 returns on record between 2019 and 2023, listing 828 overdue payments to 69 micro and small suppliers. The latest return was filed on 29 Aug 2023.